# BPC-157 TB-500 FAQ: The Blend, the Evidence, the Access, Answered

> BPC-157 TB-500 questions answered from the published record: what the blend is, how the two peptides work, dosing context, the synergy gap, safety, and the FDA 503A and WADA status.

Twenty-five questions about the two-peptide blend, each answered from a cited study or the audited FDA status — and each pointing to the gap where the combination data should be.

## What is the Wolverine peptide blend?

A research-community name for a two-peptide pairing of BPC-157 with TB-500, discussed as a tissue-repair stack. It is not a single chemical entity or an approved product. The combination's human effect is unproven, and no controlled trial of the pairing exists [9].

## What is BPC-157 and TB-500?

BPC-157 is a synthetic 15-amino-acid pentadecapeptide — the cytoprotective and angiogenic component. TB-500 is a synthetic Ac-LKKTETQ heptapeptide from the actin-binding region of Thymosin Beta-4 — the cytoskeletal and cell-migration component [1][3]. Two distinct peptides, paired.

## What is the difference between BPC-157 and TB-500?

BPC-157 is a 15-mer gastric-juice-derived peptide acting locally via VEGFR2 and eNOS; TB-500 is a 7-mer fragment of Thymosin Beta-4 acting via G-actin sequestration [2][3]. Different size (~1419.5 Da versus ~889 Da), different origin, different mechanism, paired for complementary effects.

## What is the BPC-157 and TB-500 blend used for in research?

It is studied in preclinical, mostly rodent, tissue-repair models: BPC-157 in tendon, ligament, and wound work [1]; TB-500 / Thymosin Beta-4 in cell migration, re-epithelialization, and angiogenesis [4]. No human combination efficacy is established [9].

## Why are BPC-157 and TB-500 combined (the Wolverine stack)?

The rationale pairs BPC-157's local cytoprotective and pro-angiogenic signal with TB-500's actin-sequestration and cell-migration signal as complementary mechanisms [2][3]. This synergy is a theoretical extrapolation, not a finding from any controlled combination study.

## Is there any study showing BPC-157 and TB-500 work better together (synergy)?

No. A 2025 systematic review of BPC-157 — 36 studies, only one human — makes no mention of TB-500 or combination use, and no peer-reviewed study defines a synergy ratio, dose, or endpoint for the two given together [9].

## Are there human clinical trials on the BPC-157 + TB-500 combination?

There are no controlled clinical trials of the combination. Human data exist only for the individual constituents and are thin: three small BPC-157 pilots, and human data labeled "TB-500" are for full-length Thymosin Beta-4, not the heptapeptide [6][7][9].

## Does the BPC-157 TB-500 blend help tendon and ligament injuries?

In animal models, BPC-157 accelerated healing of a transected rat Achilles tendon across biomechanical, functional, and microscopic measures [1]. These are preclinical, single-compound findings; the blend's effect in humans is unproven [9].

## Does BPC-157 and TB-500 help muscle tears and recovery?

Recovery interest rests on preclinical work — BPC-157 tendon and tissue studies [1] and Thymosin Beta-4 cell-migration findings [4]. No controlled human study supports muscle-recovery claims for the blend [10].

## How does TB-500 work (actin / Thymosin Beta-4)?

TB-500's LKKTETQ motif binds monomeric G-actin one-to-one. Crystallography of a Thymosin Beta-4-actin complex showed it sequesters the monomer by capping both ends, regulating the cytoskeletal dynamics that drive cell migration [3].

## How does BPC-157 work compared to TB-500?

BPC-157 acts through a local cytoprotective and pro-angiogenic route — VEGFR2-Akt-eNOS up-regulation [2]. TB-500 acts through intracellular actin sequestration governing cell migration [3]. The two are described as complementary but largely non-overlapping.

## Do BPC-157 and TB-500 promote angiogenesis (new blood vessels)?

BPC-157 is pro-angiogenic via VEGFR2 up-regulation and internalization with downstream VEGFR2-Akt-eNOS signaling; TB-500 / Thymosin Beta-4 promotes angiogenesis through endothelial migration [2][4]. Both are reported in animal and in-vitro models.

## What is the half-life of BPC-157 and TB-500?

A rat-and-dog pharmacokinetic study reported BPC-157's elimination half-life as under 30 minutes [5]. No validated human half-life exists for either constituent at research doses, and none for the blend [6][7].

## How do you reconstitute a BPC-157 / TB-500 blend (10mg)?

Both are supplied as lyophilized powders reconstituted in bacteriostatic or sterile water and refrigerated for research handling. Product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed [8].

## How often should you inject BPC-157 and TB-500?

There is no validated dosing schedule for the blend; community "loading then maintenance" protocols have no controlled-trial basis [9]. The underlying animal studies used per-body-weight doses that are not human guidance [1].

## How much BPC-157 and TB-500 should be used per week?

No validated blend dose exists. Commercial vials commonly pair fixed combined masses (for example ~10 mg plus ~10 mg), but no peer-reviewed combination dose-finding study supports any weekly amount [9].

## Can BPC-157 and TB-500 be taken orally instead of injected?

BPC-157 is studied as a "stable gastric" peptide and oral blend products are marketed, but those products lack validated pharmacokinetics [5]. Subcutaneous and intramuscular are the predominant research-community routes.

## Can you mix BPC-157 with TB-500 in the same syringe?

A common community practice is to reconstitute the two peptides separately or in a shared vial. There is no controlled study defining a combined formulation, and unregulated material has unverified ratio and purity [8].

## How do you cycle BPC-157 and TB-500?

Community "loading then maintenance" cycling protocols have no controlled-trial basis. No validated blend schedule exists; described findings are preclinical and dosed per body weight in animals [9].

## What are the side effects of BPC-157 and TB-500?

Human safety data are limited to the individual constituents — full-length Thymosin Beta-4 was well tolerated in intravenous Phase 1 studies [6][7]. The blend's combination safety is unproven, and reviews note potential for serious harm with unapproved peptides [10].

## Does TB-500 cause cancer or promote tumor growth?

Thymosin Beta-4 is implicated in tumor metastasis and angiogenesis; the same pro-migratory, pro-angiogenic properties that aid repair could theoretically support tumor progression [4]. This is a safety consideration, not a demonstrated outcome in blend users.

## Are BPC-157 and TB-500 FDA approved or banned by WADA?

Neither is FDA-approved for human use, and the blend has no approved indication; both are currently in the FDA's Category 2 for 503A compounding [12]. Both are also prohibited by WADA — BPC-157 under S0 non-approved substances, TB-500 / thymosin beta-4 under prohibited peptide and growth-factor categories. The audited detail is on the legal-status page [13][14].

## Is Wolverine (BPC-157 + TB-500) legal?

Neither constituent is an FDA-approved drug and the blend has no approved indication; both are currently in the FDA's Category 2 for 503A compounding [12]. The audited FDA 503A and WADA detail is on the legal-status page [13][14].

## Can you get BPC-157 from a compounding pharmacy?

Currently, access is restricted: BPC-157 is in the FDA's Category 2 of bulk drug substances (effective September 29, 2023), which is not within the FDA's enforcement-discretion policy for 503A compounding [12][13]. The audited regulatory detail is on the legal-status page.

## What is the FDA 503A status of Wolverine?

Both constituents are unapproved for human use and currently in FDA Category 2 for 503A compounding (effective September 29, 2023); both are on the FDA's scheduled July 23-24, 2026 advisory-committee agenda as candidates for the 503A bulks list [12][14]. See the audited detail on the legal-status page.

---

A dark-gallery digest of the BPC-157 and TB-500 record — every study hung as a cited specimen, the access status read first, and no clinic, vendor, or prescription behind the glass.